305 related articles for article (PubMed ID: 33830351)
1. Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis.
Aoki K; Matsunaga S; Ito S; Shibahara T; Nomura T; Matsuzaki H; Abe S; Yamaguchi A
J Bone Miner Metab; 2021 Sep; 39(5):737-747. PubMed ID: 33830351
[TBL] [Abstract][Full Text] [Related]
2. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
3. Intraindividual comparison of preoperative (99m)Tc-MDP SPECT/CT and intraoperative and histopathological findings in patients with bisphosphonate- or denosumab-related osteonecrosis of the jaw.
Assaf AT; Zrnc TA; Remus CC; Adam G; Zustin J; Heiland M; Friedrich RE; Derlin T
J Craniomaxillofac Surg; 2015 Oct; 43(8):1461-9. PubMed ID: 26232916
[TBL] [Abstract][Full Text] [Related]
4. Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice.
Hayano H; Kuroshima S; Sasaki M; Tamaki S; Inoue M; Ishisaki A; Sawase T
Bone; 2020 Jun; 135():115308. PubMed ID: 32142911
[TBL] [Abstract][Full Text] [Related]
5. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
6. Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases.
Yuan A; Munz A; Reinert S; Hoefert S
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Feb; 129(2):133-140. PubMed ID: 31606424
[TBL] [Abstract][Full Text] [Related]
7. Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study.
Hasegawa T; Ueda N; Yamada SI; Kato S; Iwata E; Hayashida S; Kojima Y; Shinohara M; Tojo I; Nakahara H; Yamaguchi T; Kirita T; Kurita H; Shibuya Y; Soutome S; Akashi M;
Osteoporos Int; 2021 Nov; 32(11):2323-2333. PubMed ID: 33997909
[TBL] [Abstract][Full Text] [Related]
8. Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).
Endo Y; Kumamoto H; Nakamura M; Sugawara S; Takano-Yamamoto T; Sasaki K; Takahashi T
Biol Pharm Bull; 2017; 40(6):739-750. PubMed ID: 28566618
[TBL] [Abstract][Full Text] [Related]
9. Denosumab-related osteonecrosis of the jaws: successful management with a conservative surgical approach.
de Souza Póvoa RC; Marlierè DA; da Silveira HM; Pires FR
Spec Care Dentist; 2016 Jul; 36(4):231-6. PubMed ID: 26859582
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the cone beam computed tomography findings in medication-related osteonecrosis of the jaws related to denosumab versus bisphosphonates: an observational pilot study.
Pichardo SEC; Broek FWT; Fiocco M; Appelman-Dijkstra NM; van Merkesteyn JPR
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Apr; 129(4):411-417. PubMed ID: 32001241
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series.
Aljohani S; Gaudin R; Weiser J; Tröltzsch M; Ehrenfeld M; Kaeppler G; Smeets R; Otto S
J Craniomaxillofac Surg; 2018 Sep; 46(9):1515-1525. PubMed ID: 29983309
[TBL] [Abstract][Full Text] [Related]
13. [Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].
Takaoka K; Kishimoto H
Nihon Yakurigaku Zasshi; 2019; 153(1):22-27. PubMed ID: 30643088
[TBL] [Abstract][Full Text] [Related]
14. Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan.
Nashi M; Kishimoto H; Kobayashi M; Tachibana A; Suematsu M; Fujiwara S; Ota Y; Hashitani S; Shibatsuji T; Nishida T; Fujimura K; Furudoi S; Ishida Y; Ishii S; Fujita T; Iwai S; Shigeta T; Harada T; Miyai D; Takeda D; Akashi M; Noguchi K; Takenobu T
J Dent Sci; 2023 Jul; 18(3):1156-1163. PubMed ID: 37404599
[TBL] [Abstract][Full Text] [Related]
15. Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ).
Hoefert S; Yuan A; Munz A; Grimm M; Elayouti A; Reinert S
J Craniomaxillofac Surg; 2017 Apr; 45(4):570-578. PubMed ID: 28238559
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons.
Yoneda T; Hagino H; Sugimoto T; Ohta H; Takahashi S; Soen S; Taguchi A; Toyosawa S; Nagata T; Urade M
J Bone Miner Metab; 2010 Jul; 28(4):365-83. PubMed ID: 20333419
[TBL] [Abstract][Full Text] [Related]
17. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-related osteonecrosis of the jaw: an overview.
Ruggiero SL
Ann N Y Acad Sci; 2011 Feb; 1218():38-46. PubMed ID: 20946580
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle?
Otto S; Hafner S; Mast G; Tischer T; Volkmer E; Schieker M; Stürzenbaum SR; von Tresckow E; Kolk A; Ehrenfeld M; Pautke C
J Oral Maxillofac Surg; 2010 May; 68(5):1158-61. PubMed ID: 20138420
[TBL] [Abstract][Full Text] [Related]
20. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.
Assaf AT; Smeets R; Riecke B; Weise E; Gröbe A; Blessmann M; Steiner T; Wikner J; Friedrich RE; Heiland M; Hoelzle F; Gerhards F
Anticancer Res; 2013 Sep; 33(9):3917-24. PubMed ID: 24023329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
